Recent funding and strategic partnerships spotlight accelerated progress in gene and cell therapy. Epigenic Therapeutics secured $60 million in Series B financing to propel CRISPR epigenetic therapies targeting chronic hepatitis B and hypercholesterolemia. NRG Therapeutics closed a £50 million ($67 million) Series B to advance mitochondrial pore inhibitors in neurodegenerative diseases including ALS. Matica Biotechnology and Cirsium Biosciences initiated collaborations to support innovation in AAV manufacturing, reflecting growing investment in scalable gene therapy production.